VivoSim Labs Shares Soar 33.9% on FDA Animal Testing Phase-Out and Strategic Moves

Introduction

VivoSim Labs Inc (Nasdaq: VIVS) is a pharmaceutical and biotechnology services company providing non-animal toxicology assessments. The firm’s NAMkind™ 3D liver and intestinal models utilize primary human cells combined with AI analytics to deliver early, human-relevant safety insights. As of today’s market close, the stock price on NASDAQ is $3.08, reflecting a change of 33.91% with a trading volume of 7,175,560 shares.

Corporate structure and workforce

Founded as Organovo Holdings, Inc., the company was rebranded to VivoSim Labs and operates from San Diego with a workforce categorized as small-to-mid-size. Public filings and its LinkedIn profile indicate a headcount in the range of 11–50 employees, which includes toxicologists, cell biologists, data scientists, and regulatory experts. The organization's governance is led by Chairman Keith Murphy, with support from scientifically credentialed executive officers.

Toxicology Models by Shubham Dhage

Recent developments and news

• March 20, 2025: Executed a 1-for-12 reverse stock split in compliance with NASDAQ listing standards.
• April 10, 2025: The U.S. Food and Drug Administration announced intentions to phase out animal testing, which may facilitate the adoption of VivoSim’s NAMkind™ models.
• April 23, 2025: Organovo confirmed that VivoSim Labs will continue its 3D bioprinting initiatives.
• April 24, 2025: VivoSim emerged from stealth mode, unveiling liver and intestinal organoid services intended to assist in the evaluation of drug candidates prior to Investigational New Drug (IND) applications.
• August 14, 2025: Filed an 8-K indicating material events under Items 5.02, 7.01, and 9.01, which included updates regarding partnerships and management changes.
• August 28, 2025: Registered an additional 147,916 shares under its 2022 Equity Incentive Plan (S-8 filing), bringing the total shares available for employee awards to 250,978.
• September 26, 2025: Submitted a request to withdraw its Form S-1 registration (RW filing), suggesting a strategic pause on public offerings while retaining SEC filing fees for future initiatives.
• October 30, 2025: The stock price increased by 33.91% with trading volume of approximately 7.2 million shares.

Financial and strategic analysis

VivoSim’s stock price recovery to $3.08 follows the reverse stock split in March 2025 and a series of corporate filings. The withdrawal of the S-1 registration on September 26, 2025, indicates management may prioritize internal financing or strategic partnerships over immediate public capital raises. The expansion of the 2022 Equity Incentive Plan reflects a commitment to talent retention. In the absence of detailed revenue disclosures, the firm's valuation relies on its capability to implement NAMkind™ models at three critical stages: prospective screens, translational bridging, and investigative toxicology. VivoSim is targeting a share of the $10 billion animal-testing market.

Market position and industry context

VivoSim operates at the intersection of biotechnology services and regulatory reform. Its NAMkind™ platform addresses challenges within the pharmaceutical industry, specifically late-stage drug failures, discrepancies in cross-species safety data, and high research and development costs by offering human-relevant, modular assays. The FDA’s announcement on April 10, 2025, to phase out animal testing may provide regulatory support for VivoSim's offerings. Competitors include other contract research organizations (CROs) and organoid developers; however, VivoSim distinguishes itself through the integration of AI analytics, customized assay panels, and species-specific organoids.

tl;dr

On October 30, 2025, VivoSim Labs’ stock rose 33.91% to $3.08 amid significant trading activity. Since emerging from stealth mode on April 24, 2025, the company has aligned its NAMkind™ toxicology models with the FDA’s animal-testing phase-out, executed a 1-for-12 reverse stock split in March, expanded its employee equity plan in August, and withdrew its S-1 registration in September. Management is focusing on internal funding and partnerships while seeking to capture opportunities within the $10 billion animal-testing market.